€8M upfrontDivestiture / carve-outHealthcare & Life Sciences
Armed Cell Therapeutics buys Lakefront's CAR-T programs
Belgian startup Armed Cell, chaired by ex-Galapagos CEO Paul Stoffels, is paying Lakefront Biotherapeutics €8 million upfront plus up to $230 million in future payments for its CAR-T assets.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Get healthcare deals like this every morning
The day's biggest deals in five minutes. Free, with no paywalled links.